4-[(1RS)-2-methoxy-1-(naphthalen-2-yl)ethyl]piperidine monohydrochloride | 1207437-15-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-[(1RS)-2-methoxy-1-(naphthalen-2-yl)ethyl]piperidine monohydrochloride
• 英文别名: 4-(2-Methoxy-1-naphthalen-2-ylethyl)piperidine;hydrochloride；4-(2-methoxy-1-naphthalen-2-ylethyl)piperidine;hydrochloride
• CAS: 1207437-15-7
• 化学式: C₁₈H₂₃NO*ClH
• 分子量: 305.848
• InChiKey: AQLYDOOFZXWOAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.99
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  21.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-萘乙腈 在 盐酸 、 sodium tetrahydroborate 、 硼烷四氢呋喃络合物 、 乙醇 、 水 、 氢溴酸 、 sodium methylate 、 sodium hydride 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 28.08h， 生成 4-[(1RS)-2-methoxy-1-(naphthalen-2-yl)ethyl]piperidine monohydrochloride
  参考文献：
  名称：

  Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds

  摘要：

  A novel triple reuptake inhibitor with low potential of liabilities associated with cationic amphiphilic drug (CAD) was identified following an analysis of existing drugs. Low molecular weight (MW < ca. 300), low aromatic ring count (number = 1) and reduced lipophilicity (ClogP < 3.5) were hypothesized to be key factors to avoid the CAD associated liabilities (CYP2D6 inhibition, hERG inhibition and phospholipidosis). Based on the hypothesis, a series of piperidine compounds was designed with consideration of the common characteristic features of CNS drugs. Optimization of the side chain by adjusting overall lipophilicity suggested that incorporation of a methoxymethyl group could provide compounds with a balance of both potent reuptake inhibition and low liability potential. Compound (S)-3a showed a potent antidepressant-like effect in the mice tail suspension test (MED = 10 mg/kg, p.o.), proportional monoamine transporter occupancies and enhancement of monoamine concentrations in mouse prefrontal cortex. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.025

文献信息

• Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds
  作者：Yuji Ishichi、Eiji Kimura、Eiji Honda、Masato Yoshikawa、Takashi Nakahata、Yasuko Terao、Atsuko Suzuki、Takayuki Kawai、Yuuichi Arakawa、Hiroyuki Ohta、Naoyuki Kanzaki、Hideyuki Nakagawa、Jun Terauchi

  DOI：10.1016/j.bmc.2013.05.025

  日期：2013.8

  A novel triple reuptake inhibitor with low potential of liabilities associated with cationic amphiphilic drug (CAD) was identified following an analysis of existing drugs. Low molecular weight (MW < ca. 300), low aromatic ring count (number = 1) and reduced lipophilicity (ClogP < 3.5) were hypothesized to be key factors to avoid the CAD associated liabilities (CYP2D6 inhibition, hERG inhibition and phospholipidosis). Based on the hypothesis, a series of piperidine compounds was designed with consideration of the common characteristic features of CNS drugs. Optimization of the side chain by adjusting overall lipophilicity suggested that incorporation of a methoxymethyl group could provide compounds with a balance of both potent reuptake inhibition and low liability potential. Compound (S)-3a showed a potent antidepressant-like effect in the mice tail suspension test (MED = 10 mg/kg, p.o.), proportional monoamine transporter occupancies and enhancement of monoamine concentrations in mouse prefrontal cortex. (C) 2013 Elsevier Ltd. All rights reserved.